Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07765966

Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias

Conditions: Immune Thrombocytopenia (ITP)

Sex: All

Ages: 18 Years – 75 Years

Healthy volunteers: No

Phase: PHASE1

Enrollment: 27

Sponsor: RiboX Therapeutics Ltd.

Summary

The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.

Eligibility Criteria

Inclusion Criteria: * 18-75 years of age * Diagnosed with primary ITP * Relapsed or refractory ITP Exclusion Criteria: * Allergy or hypersensitivity to messenger ribonucleic acid (mRNA) vaccines or other RNA-LNP products * Any active infection * Heart failure, reduced kidney function, or liver abnormalities

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07765966). StuddyBuddy aggregates publicly available trial information.